151 related articles for article (PubMed ID: 27013194)
1. Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest.
Schaaf L; Schwab M; Ulmer C; Heine S; Mürdter TE; Schmid JO; Sauer G; Aulitzky WE; van der Kuip H
Cancer Res; 2016 May; 76(10):2868-75. PubMed ID: 27013194
[TBL] [Abstract][Full Text] [Related]
2. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia.
Pelz JO; Vetterlein M; Grimmig T; Kerscher AG; Moll E; Lazariotou M; Matthes N; Faber M; Germer CT; Waaga-Gasser AM; Gasser M
Ann Surg Oncol; 2013 Apr; 20(4):1105-13. PubMed ID: 23456378
[TBL] [Abstract][Full Text] [Related]
4. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.
Oei AL; van Leeuwen CM; Ahire VR; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJA; Crezee J; Kok HP; Krawczyk PM; Kanaar R; Franken NAP
Oncotarget; 2017 Apr; 8(17):28116-28124. PubMed ID: 28427225
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin resistance associated with PARP hyperactivation.
Michels J; Vitale I; Galluzzi L; Adam J; Olaussen KA; Kepp O; Senovilla L; Talhaoui I; Guegan J; Enot DP; Talbot M; Robin A; Girard P; Oréar C; Lissa D; Sukkurwala AQ; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Dessen P; Saparbaev M; Soria JC; Castedo M; Kroemer G
Cancer Res; 2013 Apr; 73(7):2271-80. PubMed ID: 23554447
[TBL] [Abstract][Full Text] [Related]
6. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
7. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance.
Kanev PB; Atemin A; Stoynov S; Aleksandrov R
Semin Oncol; 2024; 51(1-2):2-18. PubMed ID: 37714792
[TBL] [Abstract][Full Text] [Related]
8. Response of OVCAR-3 Cells to Cisplatin and Hyperthermia: Does Hyperthermia Really Matter?
Sukovas A; Cesna V; Jasukaitiene A; Barauskas G; Nadisauskiene RJ; Dambrauskas Z; Paskauskas S; Gulbinas A
Anticancer Res; 2017 Sep; 37(9):5011-5018. PubMed ID: 28870927
[TBL] [Abstract][Full Text] [Related]
9. Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1.
Xiao M; Guo J; Xie L; Yang C; Gong L; Wang Z; Cai J
Mol Cancer Res; 2020 Mar; 18(3):436-447. PubMed ID: 31722968
[TBL] [Abstract][Full Text] [Related]
10. Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
Oei AL; Ahire VR; van Leeuwen CM; Ten Cate R; Stalpers LJA; Crezee J; Kok HP; Franken NAP
Int J Hyperthermia; 2018 Feb; 34(1):39-48. PubMed ID: 28540821
[TBL] [Abstract][Full Text] [Related]
11. Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors.
Mimnaugh EG; Yunmbam MK; Li Q; Bonvini P; Hwang SG; Trepel J; Reed E; Neckers L
Biochem Pharmacol; 2000 Nov; 60(9):1343-54. PubMed ID: 11008128
[TBL] [Abstract][Full Text] [Related]
12. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
[TBL] [Abstract][Full Text] [Related]
14. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy.
Nadin SB; Vargas-Roig LM; Drago G; Ibarra J; Ciocca DR
Cancer Lett; 2006 Jul; 239(1):84-97. PubMed ID: 16143448
[TBL] [Abstract][Full Text] [Related]
15. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
Chen G; Zeller WJ; Todorov DK
Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
[TBL] [Abstract][Full Text] [Related]
16. Sensitizing thermochemotherapy with a PARP1-inhibitor.
Oei AL; Vriend LE; van Leeuwen CM; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJ; Crezee J; Kanaar R; Kok HP; Krawczyk PM; Franken NA
Oncotarget; 2017 Mar; 8(10):16303-16312. PubMed ID: 27557507
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin induces early embryo apoptosis by inhibiting poly(ADP ribose) polymerase.
Wang QL; Sun SC; Han J; Kwak YC; Kim NH; Cui XS
In Vivo; 2012; 26(5):827-34. PubMed ID: 22949597
[TBL] [Abstract][Full Text] [Related]
18. Interactions of mild hyperthermia, cisplatin and split dose irradiation in human ovarian carcinoma cells.
Raaphorst GP; Miao J; Stewart D; Ng CE
Cancer Chemother Pharmacol; 1998; 41(6):491-6. PubMed ID: 9554594
[TBL] [Abstract][Full Text] [Related]
19. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
20. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]